Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/ct2/show/NCT05441930
Registration number
NCT05441930
Ethics application status
Date submitted
19/06/2022
Date registered
1/07/2022
Date last updated
12/04/2024
Titles & IDs
Public title
A Study of Levofloxacin Ocular Implant in Patients Undergoing Routine Bilateral Cataract Surgery
Query!
Scientific title
An Interventional, Open Label, Controlled, Randomized, Pairwise, Phase Ib Safety, Tolerability and Pharmacokinetic (PK) Study of Levofloxacin Ocular Implant in Patients Undergoing Routine Bilateral Cataract Surgery
Query!
Secondary ID [1]
0
0
LEVO-CS102
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Cataract
0
0
Query!
Condition category
Condition code
Eye
0
0
0
0
Query!
Diseases / disorders of the eye
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - Levofloxacin Ocular Implant
Treatment: Drugs - Control
Experimental: Levofloxacin Ocular Implant - Biphasic levofloxacin antibiotic implant
Active Comparator: Control - Commercially available topical medications as per LEVO-CS102 Surgical Therapy Procedure.
Treatment: Drugs: Levofloxacin Ocular Implant
Levofloxacin Ocular Implant an implant that delivers a bolus dose of levofloxacin and a constant daily dose for a further 5-7 days.
Treatment: Drugs: Control
Commercially available topical medications as per LEVO-CS102 Surgical Therapy Procedure.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Safety of the Levofloxacin Ocular Implant
Query!
Assessment method [1]
0
0
Descriptive summary statistics will be used to assess the number and frequency of ocular and non ocular adverse events
Query!
Timepoint [1]
0
0
Day 90
Query!
Primary outcome [2]
0
0
Levofloxacin concentration in aqueous humor at Day 5 in treated eyes
Query!
Assessment method [2]
0
0
To determine levofloxacin concentration in aqueous humor at Day 5 in eyes with the Levofloxacin Ocular Implant to facilitate dose adjustment for Phase II studies.
Query!
Timepoint [2]
0
0
Day 5
Query!
Secondary outcome [1]
0
0
Number of actuations required to administer the implant
Query!
Assessment method [1]
0
0
Clinicians administering the implant will record the number of actuations required to use the custom-built administration device
Query!
Timepoint [1]
0
0
Day 0
Query!
Eligibility
Key inclusion criteria
Key Inclusion Criteria
1. Male or female subjects 18 years of age or older.
2. Willing and able to understand and sign an informed consent form prior to any
study-related procedures.
3. Willing and able to follow study instructions, and able to be present for the required
study visits/assessments for the duration of the study.
4. Diagnosis of cataract in both eyes scheduled for sequential bilateral elective
cataract extraction by phacoemulsification and posterior chamber IOL implantation not
combined with any other surgery except femtosecond laser.
5. Minimum endothelial cell density (ECD) in both eyes of greater than or equal to 2000
cells per mm2.
6. Fully vaccinated against COVID-19, as evidenced by vaccination record.
Key Opthalmic
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
Exclusion Criteria
Ophthalmic:
1. Have a history of or current uveitis, macular edema (cystoid or diabetic), diabetic
retinopathy, retinal vein occlusion and neovascular glaucoma, corneal conditions such
as keratitis, corneal edema or advanced macular degeneration, which in the opinion of
the investigator would interfere with study assessments and confound the data.
2. In the opinion of the investigator or reading center, have confluent central corneal
guttatae, multiple central guttatae greater than a single cell, or corneal disease or
abnormality that would prevent specular microscopy corneal scans.
3. Aphakia or low vision or monocular.
4. Have had any intraocular surgery, glaucoma surgery (including but not limited to
filtering surgery like trabeculectomy, Ahmed valve, etc) or cornea/refractive surgery
within the past 6 months or anticipate a need for eye surgery (including laser) during
the study period.
5. Use of prostaglandin (PG) analogues within 60 days prior to Screening or during the
course of the study.
6. Subjects with clinically diagnosed Fuchs' Endothelial Corneal Dystrophy (FECD)/
history of keratoplasty.
7. Subjects for whom an intra-ocular or glaucoma device procedure is planned during the
cataract procedure, during study participation or has been previously undertaken.
8. Have a current retinal detachment or history of blunt trauma in either eye.
9. Subject who in the opinion of the surgeon has a high risk of the posterior capsule
being compromised/zonular dehiscence during cataract surgery.
10. Intraoperative complications during the cataract surgery including posterior capsule
rupture, zonular dehiscence, non-placement of Posterior Chamber Intra Ocular Lens
(PCIOL), vitreous prolapse, lens fragments in the vitreous, placement of Anterior
Chamber Intra Ocular Lens (ACIOL), uncontrolled bleeding /hyphema.
11. Known sensitivity to any component of the product (e.g. fluoroquinolone or
polyurethane sensitivity), or to topical therapy used during course of study (e.g.,
povidone iodine, or anesthetics).
12. Used fluoroquinolone antibiotics (topically, orally or systemically) during the 4
weeks before screening visit.
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 1
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Withdrawn
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
23/06/2023
Query!
Actual
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
14/03/2024
Query!
Actual
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
0
Query!
Recruitment in Australia
Recruitment state(s)
VIC
Query!
Recruitment hospital [1]
0
0
Melbourne Eye Specialists - Fitzroy
Query!
Recruitment postcode(s) [1]
0
0
3065 - Fitzroy
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Missouri
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
South Carolina
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Query!
Name
PolyActiva Pty Ltd
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
Open label controlled interventional study in eyes in up to 12 subjects (24 eyes) scheduled
for uncomplicated bilateral cataract surgery on separate days.
Query!
Trial website
https://clinicaltrials.gov/ct2/show/NCT05441930
Query!
Trial related presentations / publications
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Michael Coote, MD
Query!
Address
0
0
Melbourne Eye Specialists
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
Summary Results
For IPD and results data, please see
https://clinicaltrials.gov/ct2/show/NCT05441930
Download to PDF